Winnie Chan1, Shui Hao Chin2, Anna C Whittaker3, David Jones4, Okdeep Kaur5, Jos A Bosch6, Richard Borrows7. 1. Department of Nephrology & Kidney Transplantation, Area 5, Level 7, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom; Department of Nutrition & Dietetics, Therapy Services South Suite, 1st Floor, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom; School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom. Electronic address: Winnie.Chan@uhb.nhs.uk. 2. Department of Cardiovascular Sciences, Clinical Sciences Wing, University of Leicester, Glenfield Hospital, Leicester, United Kingdom. 3. School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom; Faculty of Health Sciences and Sport, University of Stirling, Stirling, Scotland, United Kingdom. 4. School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom. 5. Department of Nephrology & Kidney Transplantation, Area 5, Level 7, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom. 6. School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom; Department of Clinical Psychology, University of Amsterdam, Amsterdam, the Netherlands. 7. Department of Nephrology & Kidney Transplantation, Area 5, Level 7, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom; Center for Translational Inflammation Research, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Abstract
OBJECTIVE: Sarcopenia, defined as loss of both muscle strength and mass, is associated with inferior clinical outcomes and quality of life (QoL) in chronic kidney disease, but its effects are unknown in kidney transplantation. Obesity confers increased mortality risk and compromises QoL in kidney transplant recipients (KTRs), but the impacts of sarcopenic obesity remain unexplored. This study aimed to evaluate the associations of muscle strength and mass, sarcopenia, and sarcopenic obesity with clinical outcomes and QoL in KTRs. METHODS: This prospective longitudinal study enrolled 128 KTRs ≥1-year posttransplantation. Low muscle strength (by handgrip strength) and mass (by bioimpedance analysis), and a combination of both (sarcopenia) were defined as < reference cutoffs for corresponding indices. Sarcopenic obesity was defined as sarcopenia combined with fulfillment of ≥2 out of 3 criteria from (1) body mass index ≥30 kg/m2, (2) bioimpedance analysis-derived fat mass > reference cutoffs, and (3) waist circumference > World Health Organization cutoffs. Prospective follow-up data on mortality and hospitalization were collected. QoL was evaluated using Medical Outcomes Study Short Form-36 questionnaire. RESULTS: Median follow-up duration was 64 (60-72) months. Low muscle strength was independently associated with the composite endpoint of mortality and hospitalization (hazard ratio = 2.45; P = .006), and QoL (physical-related: β = -12.2; P = .04; mental-related: β = -9.9; P = .04). Low muscle mass (β = -8.8; P = .04) and sarcopenia (β = -14.7; P = .03) were associated with physical-related QoL only. No independent associations were found between muscle mass, sarcopenia, and sarcopenic obesity with the composite outcome of mortality and hospitalization. CONCLUSION: Low muscle strength is common among KTRs, conferring poor prognosis in the medium term. Future research on strength training may prove valuable in improving kidney transplantation outcomes.
OBJECTIVE:Sarcopenia, defined as loss of both muscle strength and mass, is associated with inferior clinical outcomes and quality of life (QoL) in chronic kidney disease, but its effects are unknown in kidney transplantation. Obesity confers increased mortality risk and compromises QoL in kidney transplant recipients (KTRs), but the impacts of sarcopenic obesity remain unexplored. This study aimed to evaluate the associations of muscle strength and mass, sarcopenia, and sarcopenic obesity with clinical outcomes and QoL in KTRs. METHODS: This prospective longitudinal study enrolled 128 KTRs ≥1-year posttransplantation. Low muscle strength (by handgrip strength) and mass (by bioimpedance analysis), and a combination of both (sarcopenia) were defined as < reference cutoffs for corresponding indices. Sarcopenic obesity was defined as sarcopenia combined with fulfillment of ≥2 out of 3 criteria from (1) body mass index ≥30 kg/m2, (2) bioimpedance analysis-derived fat mass > reference cutoffs, and (3) waist circumference > World Health Organization cutoffs. Prospective follow-up data on mortality and hospitalization were collected. QoL was evaluated using Medical Outcomes Study Short Form-36 questionnaire. RESULTS: Median follow-up duration was 64 (60-72) months. Low muscle strength was independently associated with the composite endpoint of mortality and hospitalization (hazard ratio = 2.45; P = .006), and QoL (physical-related: β = -12.2; P = .04; mental-related: β = -9.9; P = .04). Low muscle mass (β = -8.8; P = .04) and sarcopenia (β = -14.7; P = .03) were associated with physical-related QoL only. No independent associations were found between muscle mass, sarcopenia, and sarcopenic obesity with the composite outcome of mortality and hospitalization. CONCLUSION: Low muscle strength is common among KTRs, conferring poor prognosis in the medium term. Future research on strength training may prove valuable in improving kidney transplantation outcomes.
Authors: Luke A Baker; Daniel S March; Thomas J Wilkinson; Roseanne E Billany; Nicolette C Bishop; Ellen M Castle; Joseph Chilcot; Mark D Davies; Matthew P M Graham-Brown; Sharlene A Greenwood; Naushad A Junglee; Archontissa M Kanavaki; Courtney J Lightfoot; Jamie H Macdonald; Gabriella M K Rossetti; Alice C Smith; James O Burton Journal: BMC Nephrol Date: 2022-02-22 Impact factor: 2.388
Authors: Milena Dos Santos Mantovani; Nyara Coelho de Carvalho; Marcos Ferreira Minicucci; Luis Gustavo Modelli de Andrade; Ricardo de Souza Cavalcante; Gabriel Berg de Almeida; Nara Aline Costa; Julhiany de Fátima da Silva; Ricardo Augusto Monteiro de Barros Almeida Journal: J Nephrol Date: 2022-09-01 Impact factor: 4.393
Authors: Jesse D Schold; Joshua J Augustine; Anne M Huml; Richard Fatica; Saul Nurko; Alvin Wee; Emilio D Poggio Journal: Am J Transplant Date: 2020-08-27 Impact factor: 8.086
Authors: Joanna Sophia J Vinke; Hanneke J C M Wouters; Suzanne P Stam; Rianne M Douwes; Adrian Post; Antonio W Gomes-Neto; Melanie M van der Klauw; Stefan P Berger; Stephan J L Bakker; Martin H De Borst; Michele F Eisenga Journal: J Cachexia Sarcopenia Muscle Date: 2022-06-03 Impact factor: 12.063
Authors: Thomas Dienemann; Susan L Ziolkowski; Shaun Bender; Simin Goral; Jin Long; Joshua F Baker; Justine Shults; Babette S Zemel; Peter P Reese; F Perry Wilson; Mary B Leonard Journal: Am J Kidney Dis Date: 2021-08-02 Impact factor: 8.860